HK Stock Market Move | ALPHAMAB-B (09966) rose more than 12% after announcing the clinical results of the HER2 dual antibody ADC subcutaneous injection compound for the first time.

ALPHAMAB-B (09966) rose more than 12%, as of the time of writing, it rose 12.67% to 5.07 Hong Kong dollars, with a turnover of 47.352 million Hong Kong dollars. On the news front, on November 13, ConnoGen Pharmaceuticals announced that a clinical trial (study number: JSKN033-102) of the high-concentration subcutaneous injection compound JSKN033, a combination of HER2 bispecific antibody drug conjugate (ADC) and PD-L1 inhibitor, met the requirements of the "Pilot Scheme for Optimizing Innovative Drug Clinical Trial Review and Approval" and was included in the pilot project by the Shanghai Food and Drug Administration (with the consent of the Center for Drug Evaluation (CDE)). The clinical trial application will be submitted to the CDE as required and is expected to undergo expedited review and approval to accelerate the initiation of Phase I/II clinical research on advanced malignant tumors. Earlier, ConnoGen announced the results of the first human clinical study of the high-concentration subcutaneous injection compound JSKN033, a combination of HER2 bispecific antibody drug conjugate (ADC) and PD-L1 inhibitor. This study was selected as a breakthrough abstract at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in 2024, and was presented for the first time in poster form during the conference. The study concluded that JSKN033 has good safety and showed encouraging anti-tumor activity in patients with solid tumors showing disease progression after multiple-line treatments. This study further demonstrates the potential of ADC in combination with immunotherapy, and supports continued exploration of JSKN033.